Research progress of intravitreal injections for nonarteritic anterior ischemic optic neuropathy

Authors: He Lu,  Chen Changzheng
DOI: 10.3760/cma.j.cn115989-20201104-00739
Published 2021-07-10
Cite asChin J Exp Ophthalmol, 2021, 39(7): 641-644.

Abstract

Nonarteritic anterior ischemic optic neuropathy (NAION) is a common type of acute optic neuropathy in elderly, characterized by optic disc edema and visual field defect.At present, there is no generally accepted treatment, and the treatment of NAION is to control systemic disease and other risk factors, reduce optic disc edema, nurture nerve and improve microcirculation.In recent years, intravitreal drug injection has been used as a new therapy of NAION.It can make drug reach the target issue in the eye rapidly and maintain a relatively high concentration, which can enhance the efficacy without causing severe systemic complication.In this article, the effect of intravitreal injection of anti-vascular endothelial growth factor, triamcinolone acetonide, and erythropoietin in NAION was reviewed.

Key words:

Nonarteritic anterior ischemic optic neuropathy; Intravitreal injection; Glucocorticoid; Anti-vascular endothelial growth factor

Contributor Information

He Lu

Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan 430060, China

Chen Changzheng

Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan 430060, China

(Read 6 times, 1 visits today)
Updated: July 27, 2021 — 1:10 am